Eva Lengfelder

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Medicine, Immunology, Oncology +7

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

Thomas Büchner, Wolfgang E. Berdel, Claudia Haferlach et al. · Journal of Clinical Oncology · 2008 · 337 citations

Medicine, Oncology, Pharmacology +13

Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.

Thomas Büchner, Wolfgang Hiddemann, Bernhard Wörmann et al. · PubMed · 1999 · 321 citations

Medicine, Oncology, Pharmacology +17

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Giovanni Barosi, Ruben A. Mesa, Guido Finazzi et al. · Blood · 2013 · 289 citations

Medicine, Hematology, Internal Medicine +3

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler et al. · Journal of Clinical Oncology · 2009 · 270 citations · Full text

Medicine, Oncology, Pharmacology +17